- Home
- FT vs CRVO Comparison
FT vs CRVO Comparison
Compare FT & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- CRVO
- Stock Information
- Founded
- FT 1988
- CRVO 2001
- Country
- FT United States
- CRVO United States
- Employees
- FT N/A
- CRVO N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- CRVO Health Care
- Exchange
- FT Nasdaq
- CRVO Nasdaq
- Market Cap
- FT 189.6M
- CRVO 160.4M
- IPO Year
- FT N/A
- CRVO N/A
- Fundamental
- Price
- FT $7.59
- CRVO $9.58
- Analyst Decision
- FT
- CRVO Strong Buy
- Analyst Count
- FT 0
- CRVO 6
- Target Price
- FT N/A
- CRVO $53.67
- AVG Volume (30 Days)
- FT 63.0K
- CRVO 78.8K
- Earning Date
- FT 01-01-0001
- CRVO 11-12-2024
- Dividend Yield
- FT 7.85%
- CRVO N/A
- EPS Growth
- FT N/A
- CRVO N/A
- EPS
- FT N/A
- CRVO N/A
- Revenue
- FT N/A
- CRVO $10,066,550.00
- Revenue This Year
- FT N/A
- CRVO $54.67
- Revenue Next Year
- FT N/A
- CRVO N/A
- P/E Ratio
- FT N/A
- CRVO N/A
- Revenue Growth
- FT N/A
- CRVO 116.29
- 52 Week Low
- FT $5.97
- CRVO $5.85
- 52 Week High
- FT $7.23
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- FT 56.85
- CRVO 27.48
- Support Level
- FT $7.36
- CRVO $9.31
- Resistance Level
- FT $7.57
- CRVO $11.44
- Average True Range (ATR)
- FT 0.09
- CRVO 0.90
- MACD
- FT 0.01
- CRVO -0.23
- Stochastic Oscillator
- FT 63.79
- CRVO 6.34
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.